bioAffinity Technologies, Inc. announced a one-for-fifteen (1-for-15) reverse stock split of its common stock to comply with Nasdaq’s minimum bid price requirement. The Board approved the split following shareholder authorization at the April 30, 2026 annual meeting. The effective date is August 21, 2026, at 4:01 p.m. Eastern Time, with split-adjusted trading commencing on August 24, 2026. Post-split, approximately 592,373 shares will be issued and outstanding. Fractional shares will be paid out in cash, and exercise prices for options, warrants, and RSUs will be proportionately adjusted. The company operates in the biotechnology industry, focusing on noninvasive diagnostic tests for early-stage cancer detection.

bioAffinity Technologies entered into a distribution agreement with AvMEDICAL to market its CyPath Lung diagnostic test within the federal healthcare sector, including U.S. Department of Veteran Affairs medical centers. The partnership leverages AvMEDICAL's status as a Service-Disabled Veteran-Owned Small Business and its existing government procurement channels to expand commercial reach. bioAffinity operates in the biotechnology industry, developing noninvasive diagnostics for early detection of lung cancer.

bioAffinity Technologies, Inc. closed a private placement on August 14, 2026, raising approximately $3.6 million in net proceeds after deducting fees and expenses. The company sold 8,462,027 pre-funded warrants at $0.4657 each, accompanied by Series A and Series B warrants to purchase up to 16,924,054 shares total. Each warrant carries an initial exercise price of $0.4727 per share and expires five years after issuance. The placement agent received a 7.5% cash fee plus warrants for 253,861 shares. Proceeds will fund working capital and general corporate purposes. bioAffinity Technologies operates in the biotechnology industry, focusing on noninvasive diagnostics and early cancer detection.

bioAffinity Technologies, Inc. received a notice from Nasdaq on July 30, 2026, indicating non-compliance with the minimum bid price requirement due to its common stock closing below $1.00 for thirty consecutive business days ending July 29, 2026. The company is ineligible for the standard 180-day cure period because it executed a 1-for-30 reverse stock split on September 19, 2025. bioAffinity intends to appeal this determination on August 6, 2026, which will stay any delisting or suspension pending the Panel's decision. The company operates in the biotechnology industry.

bioAffinity Technologies, Inc. announced the publication of a clinical review and white paper by Chief Medical Officer Gordon H. Downie, MD, PhD, which presents a clinical framework for using CyPath Lung to evaluate pulmonary nodules and cancer surveillance. The publication discusses how the test's lung microenvironment analysis via sputum collection is integrated into primary care, pulmonology, and oncology practices. bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection.